Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.915 USD | +8.81% | -3.54% | -87.02% |
Apr. 11 | Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating | MT |
Apr. 10 | Transcript : Amylyx Pharmaceuticals, Inc. - Special Call |
Business Summary
Number of employees: 384
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Relyvrio (Sodium Phenylbutyrate and Taurursodiol)
100.0
%
| 22 | 100.0 % | 381 | 100.0 % | +1,612.94% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 22 | 100.0 % | 381 | 100.0 % | +1,612.94% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Justin Klee
FOU | Founder | 34 | 12-12-31 |
Josh Cohen
FOU | Founder | 33 | 12-12-31 |
Jim Frates
DFI | Director of Finance/CFO | 56 | 20-12-31 |
Chief Tech/Sci/R&D Officer | 71 | Nov. 27 | |
Lindsey Allen
IRC | Investor Relations Contact | - | - |
Gina Mazzariello
LAW | General Counsel | 53 | 22-02-22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Milne
CHM | Chairman | 80 | 14-12-31 |
Kari Firestone
BRD | Director/Board Member | - | 23-03-15 |
Paul R. Fonteyne
BRD | Director/Board Member | 63 | 21-03-28 |
Daphne Quimi
BRD | Director/Board Member | 58 | 21-06-28 |
Josh Cohen
FOU | Founder | 33 | 12-12-31 |
Justin Klee
FOU | Founder | 34 | 12-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 67,782,139 | 55,854,779 ( 82.40 %) | 0 | 82.40 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.02% | 120M | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-13.36% | 15.36B | |
-8.82% | 11.95B | |
-15.40% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- AMLX Stock
- Company Amylyx Pharmaceuticals, Inc.